Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

/PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical...

Related Keywords

Suzhou ,Jiangsu ,China ,Chinese ,Michael Molyneaux ,Patrick Lu ,Prnewswire Sirnaomics Ltd ,Drug Administration ,Chinese National Medical Products Administration ,Group Or Sirnaomics ,Squamous Cell Carcinoma ,Basal Cell Carcinoma ,Executive Director ,Chief Executive Officer ,Chief Medical Officer ,Orphan Drug Designation ,